<DOC>
	<DOCNO>NCT00901524</DOCNO>
	<brief_summary>The purpose study assess effectiveness optimize anti HCV treatment ( 360Î¼g per week PegIFN-alpha2a + 18mg/kg/j Ribavirin 6 month .</brief_summary>
	<brief_title>ANRS HC20 Effectiveness Optimized Anti HCV PegIFN-alpha2a + Ribavirin Sustained Virological Response Patients With HCV Genotype 1 4 Non Responders Co-infected With HIV</brief_title>
	<detailed_description>In patient HIV infect , success rate exceed 20 % genotype 1 4 patient . In case treatment failure , patient rarely re-treated , liver fibrosis progress rapidly . The new molecule yet available patient co-infected HIV , patient already undergo first treatment likely among last included trial evaluate effectiveness treatment . However , recent study show possible propose new treatment `` optimized '' patient hope obtain good success rate . Provide antiretroviral treatment , use high dos Peg-interferon ribavrine , support patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Hepatitis C Antibodies</mesh_term>
	<criteria>Age 18 year Weight 85 kg preinclusion visit . Documented HIV infection ( HIV positive ) HCV infection document positive PCR HCV Genotype 1 4 Compensated liver disease ( ChildPugh below/equal 6 ) Lymphocytes CD4 200/mm3 Patient answer treatment hepatitis C. Patient cover dual PegIFN + riba least three month ( wash ) Coinfection HBV ( HBsAg positive ) Neutropenia 1000/mm3 Thrombocytopenia 90000/mm3 thrombocytosis 500 000/mm3 . Hemoglobin 11 g / dL ( men woman ) Arguments radiological ( ultrasound , CT MRI ) hepatocellular carcinoma cell Antiretroviral contain didanosine ( ddI ) stavudine ( d4T ) zidovudine ( AZT ) abacavir ( ABC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>HCV Genotype 1 , 4</keyword>
	<keyword>Virological response</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>PegPegIFN- alpha 2a</keyword>
	<keyword>Viral Hepatitis ( HCV )</keyword>
</DOC>